Paolini John F. 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

CHIEF MEDICAL OFFICER

Transactions

Exercise/Conversion
Class A Ordinary Share
[F1]
2026-03-02$10.36/sh+40,000$414,400→ 101,324 total
Sale
Class A Ordinary Share
[F1][F2]
2026-03-02$44.20/sh−12,063$533,185→ 89,261 total
Sale
Class A Ordinary Share
[F1][F3]
2026-03-02$44.88/sh−22,223$997,368→ 67,038 total
Sale
Class A Ordinary Share
[F1][F4]
2026-03-02$45.92/sh−5,714$262,387→ 61,324 total
Exercise/Conversion
Share Option
[F1][F5]
2026-03-02−40,000→ 58,424 total
Exercise: $10.36Exp: 2028-02-29→ Class A Ordinary Share (40,000 underlying)

Footnotes (5)

[F1]This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.
[F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.555 and $44.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.555 and $45.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F4]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.56 and $46.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F5]The option is fully vested and exercisable.

Signature

/s/ Douglas Barry, Attorney-in-Fact|2026-03-04

Documents

1 file